AstraZeneca Loses Battle Against Generic Plendil At Federal Circuit

Law360, New York (October 4, 2004, 12:00 AM EDT) -- A U.S. appeals court has ruled that U.K.-Swedish drug maker AstraZeneca can't prevent U.S.-based Mutual Pharmaceutical Co. from selling a generic form of hypertension drug Plendil.

The U.S. Court of Appeals for the Federal Circuit in Washington ruled that Mutual's version of the drug did not infringe AstraZeneca's patent.

But in a consolation prize for AstraZeneca, the appeals court upheld the patent, which expires in 2007. The ruling could give Astra ammunition in its legal battle to prevent Ivax Corp. from marketing its own generic version...
To view the full article, register now.